Comparative Pharmacology
Head-to-head clinical analysis: TOTACILLIN versus V CILLIN K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOTACILLIN versus V CILLIN K.
TOTACILLIN vs V-CILLIN K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal: inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation. Active against gram-positive bacteria and some gram-negative bacteria.
Penicillin V exerts bactericidal activity by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life: 1.0-1.5 hours in normal renal function. Extended to 2-6 hours in renal impairment; requires dose adjustment when CrCl <30 mL/min.
0.5–1 hour (normal renal function); prolonged to 2–6 hours in renal impairment.
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <5% as unchanged drug and metabolites.
Renal: 60-90% unchanged via tubular secretion and glomerular filtration; minor biliary/fecal: <10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic